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Summary
Thephenotypesofsingle-(SKO)anddouble-knockout
(DKO) lines of dihydrofolate reductase–thymidylate
synthase (DHFR–TS) of bloodstream Trypanosoma
brucei were evaluated in vitro and in vivo. Growth of
SKO in vitro is identical to wild-type (WT) cells,
whereas DKO has an absolute requirement for thymi-
dine. Removal of thymidine from the medium triggers
growth arrest in S phase, associated with gross mor-
phological changes, followed by cell death after 60 h.
DKO is unable to infect mice, whereas the virulence of
SKO is similar to WT. Normal growth and virulence
couldberestoredbytransfectionofDKOwithT. brucei
DHFR–TS, but not with Escherichia coli TS. As pteri-
dine reductase (PTR1) levels are unchanged in SKO
andDKOcells,PTR1isnotabletocompensateforloss
of DHFR activity. Drugs such as raltitrexed or methotr-
exate with structural similarity to folic acid are up to
300-fold more potent inhibitors of WT cultured in a
novel low-folate medium, unlike hydrophobic antifols
such as trimetrexate or pyrimethamine. DKO trypano-
somes show reduced sensitivity to these inhibitors
ranging from twofold for trimetrexate to >10 000-fold
for raltitrexed. These data demonstrate that DHFR–TS
is essential for parasite survival and represents a
promising target for drug discovery.
Introduction
The post-genomic era offers unparalleled opportunities
for the identiﬁcation, characterization and validation of
novel molecular targets for drug discovery in order to
replace the currently unsatisfactory therapies for human
African trypanosomiasis. The initial selection of potential
targets from the ‘druggable genome’ is of crucial impor-
tance and known targets of current drugs in clinical use
for other diseases are a useful starting point. Folic acid
metabolism is one such area with clinical precedents
in bacterial or protozoan infections and certain human
malignancies (Blaney et al., 1984; McGuire, 2003;
Gangjee et al., 2007).
Folate and its derivatives are essential cofactors in
one-carbon metabolism that are required for the biosyn-
thesis of purines, thymidylate, serine and methionine in a
wide variety of organisms. Most bacteria, some protozoa
(e.g. malaria), fungi and plants synthesize folates de novo
using a pterin (from GTP), p-aminobenzoate (via the
chorismate pathway) and glutamate. In contrast, try-
panosomatids and their mammalian hosts lack a de novo
folate-synthesis pathway and thus require exogenous
folate for these biosynthetic functions.
Trypanosomatids have lost the ability to synthesize
purines and therefore salvage them from their environ-
ment, yet have retained the complete biosynthetic
pathway to pyrimidines necessary for nucleic acid synthe-
sis (Fig. 1). A key step in DNA synthesis is formation of
thymidylate (dTMP) catalysed by thymidylate synthase
(TS; EC 2.1.1.45) involving the reductive methylation
of deoxyuridylate (dUMP) by 5, 10-methylene-
tetrahydrofolate (CH2-H4F). The other product of this reac-
tion, dihydrofolate (H2F), is converted into tetrahydrofolate
(H4F) by dihydrofolate reductase (DHFR; EC 1.5.1.3).
Finally CH2-H4F is regenerated from H4F via either serine
hydroxymethyltransferase (EC 2.1.2.1) or the glycine
cleavage system to complete the reaction cycle. In trypa-
nosomatidsandotherparasites,DHFRandTSarefusedto
form a bifunctional protein, unlike their mammalian hosts.
Selective inhibition of DHFR or TS in prokaryotic and
eukaryotic cells results in ‘thymine-less death’ by necrosis
or apoptosis as a consequence of thymidine starvation
(Ahmad et al., 1998; Van Triest et al., 2000). However,
DHFR–TS has not been successfully exploited so far for
treatment of either trypanosomal or leishmanial infections
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reason for this is not at all clear for African trypanosomes,
in Leishmania spp., pteridine reductase (PTR1; EC
1.5.1.33) may serve to modulate or by-pass inhibition of
DHFR by classical inhibitors such as methotrexate (Nare
et al., 1997a). Gene knockout studies in avirulent lines
of Leishmania major have shown that null mutants of
DHFR–TS can be readily generated when supplemented
with thymidine (Cruz and Beverley, 1990; Cruz et al.,
1991). In contrast, virulent Leishmania show plasticity in
chromosome number in order to maintain at least one
copy of DHFR–TS (Cruz et al., 1993). Thus, DHFR–TS
may have another unidentiﬁed function in virulent lines in
addition to de novo synthesis of thymidine in avirulent
lines. Whether this requires DHFR, TS or both proteins is
not clear. Neither is it clear whether endogenous PTR1
activity is sufficient to replace DHFR in the thymidylate
cycle.
Very little is known about folate metabolism in African
trypanosomes. Comparative genomics indicates that
Trypanosoma brucei lacks a number of genes in folate-
dependent pathways that are present in L. major indicat-
ing that extrapolation from L. major to T. brucei may not
be straightforward (Berriman et al., 2005). Moreover, from
a drug discovery perspective, although T. brucei possess
both DHFR–TS and PTR1 (Gamarro et al., 1995; Dawson
et al., 2006), these enzymes show signiﬁcant differences
in structure and/or sensitivity to inhibitors to their Leish-
mania counterparts (Meek et al., 1985; Hardy et al., 1997;
Luba et al., 1998; Chowdhury et al., 1999; Gourley et al.,
1999; 2001). In this study we use genetic and chemical
methods to examine the roles of DHFR–TS in T. brucei
and assess its potential as a drug target. We also examine
the sensitivity of T. brucei bloodstream forms to known
DHFR–TS inhibitors in a novel culture medium containing
physiological levels of folate to assess the robustness of
the currently accepted standard method for whole cell
phenotypic screening of antifols (Raz et al., 1997).
Results
Generation of knockout mutants
To assess the essentiality of DHFR–TS, bloodstream-
form trypanosomes were transfected with linear con-
structs containing the drug resistance genes, puromycin
N-acetyl transferase (PAC) or hygromycin phosphotrans-
ferase (HYG) ﬂanked by the 3′- and 5′-untranslated
regions (3′-UTR and 5′-UTR respectively) of DHFR–TS.
Stable drug-resistant lines were obtained after selection
with either puromycin or hygromycin in HMI9 medium.
This culture medium contains 160 mM thymidine which
serves as a nutritional by-pass for loss of DHFR–TS
activity. The resulting single-knockout (SKO) line contain-
ing PAC was then transfected with the HYG knockout
construct and selected for resistance to puromycin and
hygromycin to obtain a double-knockout (DKO) line. A
Southern blot of a restriction enzyme digest of genomic
DNA from wild type (WT) (DHFR–TS/DHFR–TS), SKO
(DHFR–TS/dhfr–ts::PAC) and DKO (dhfr–ts::PAC/dhfr–
ts::HYG) conﬁrmed that both drug selectable markers had
correctly integrated into the S427 genome via homolo-
gous recombination at the DHFR–TS locus (Fig. 2).
Effects of folate or thymidine on growth
Cell lines were continuously passaged in various media to
determine growth phenotypes. In HMI9 medium (Fig. 3A),
WT and SKO cells grew at similar rates with doubling
times of 14.0  0.1 and 14.5  0.1 h respectively. The
DKO cell line grew at a decreased rate in the presence of
puromycin plus hygromycin with a generation time of
Fig. 1. Pathway of thymidylate synthesis
and primary site of action of inhibitors.
SHMT, serine hydroxymethyltransferase;
DHFR, dihydrofolate reductase;
TS, thymidylate synthase; O/129,
2,4-diamino-6,7-diispropylpteridine; PTR1,
pteridine reductase 1; TK, thymidine kinase;
H2F, dihydrofolate; H4F, tetrahydrofolate;
CH2-CH4F, 5, 10-methylene-tetrahydrofolate;
FdUMP, 5-ﬂuorodeoxyuridylate; GCS, glycine
cleavage system.
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growth of DKO parasites was similar to that of the other
cell lines (13.8  0.1 h). Folate-deﬁcient medium (FDM)
was developed to approximate the physiological levels
found in mouse (95 nM) (Clarke et al., 2000) and human
plasma (16–66 nM) (Hannon-Fletcher et al., 2004; Lin
et al., 2004). Similar generation times were obtained for
WT and SKO trypanosomes in FDM that are marginally
slower compared with HMI9 (18.0  0.4 and 15.8  0.4 h
respectively) (Fig. 3B). DKO grew considerably slower
(44  2 h) in this medium in the absence of drug
selection. Removal of thymidine from either medium did
not affect growth of WT or SKO cells, whereas the DKO
failed to grow and died by 72 h (Fig. 3).
To determine the effects of thymidine concentration on
growth, WT, SKO and DKO cell lines were cultured in
thymidine-free HMI9 supplemented with varying amounts
of thymidine or other pyrimidines (Fig. 4). Thymidine had
no effect on growth of WT or SKO cells up to 1 mM, but
was toxic at higher concentrations giving similar EC50
values of 7.3  0.6 and 6.7  0.7 mM for WT and SKO
respectively (Fig. 4A). In contrast, DKO cells display a
narrow window of growth, optimal at 16–64 mM, with
essentially no growth with < 2 mMo r> 2 mM thymidine
(Fig. 4B). Higher concentrations were toxic to DKO cells
with an EC50 of 380  45 mM. Other pyrimidines (thymine,
uracil or uridine) were unable to replace thymidine
(Fig. 4B). To determine at which point ‘thymidine-less
death’ was irreversible in the DKO line, cells were incu-
bated in thymidine-free HMI9 and then transferred back
into thymidine-replete HMI9 medium at intervals. Samples
were cultured for up to 14 days and examined daily for the
emergence of live, motile parasites. Under these condi-
tions, viable parasites were recovered from cultures
depleted of thymidine for up to 54 h, but not at 60 h or
thereafter (data not shown).
DNA content and morphology of WT and DKO cells
Prokaryotic and eukaryotic organisms that are aux-
otrophic for thymidine undergo cell death by necrosis or
apoptosis in response to thymidine starvation. To estab-
lish whether the DKO cells undergo a similar response,
the DNA content was analysed using a ﬂuorescence-
activated cell sorter (FACS) as illustrated in Fig. 5A–C.
For the WT cell population, 72% were in G1 phase, with
7% in S (DNA synthesis) phase and 16% in G2/M phase
(Fig. 5A). In contrast, DKO cells grown in thymidine-
deﬁcient medium were mainly arrested in S phase (58%),
with proportionally less in G1 or G2/M (Fig. 5C). In con-
trast, DKO cells grown with thymidine showed a similar
proﬁle to WT cells (Fig. 5B). Thus, thymidine starvation
Fig. 2. Genotypic analysis of WT, SKO and
DKO cells.
A. Structure of the DHFR–TS locus and
predicted replacements. The black bars
represent the 5′-UTR region upstream of the
open reading frames of DHFR–TS, PAC and
HYG used as a probe in Southern blot
analysis. Only relevant restriction enzyme
sites with expected fragment sizes are shown.
B. Southern analysis of DNA digested with
ClaI and ScaI from WT, SKO (containing PAC
and HYG respectively) and DKO cells. DNA
size markers are on the left-hand side of blots
and the estimated size of detected fragments
on the right.
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(G1) to 4N (G2/M) with arrest within S phase.
The morphology of DKO cells grown in the absence of
thymidine for 24 h was examined by scanning electron,
light and ﬂuorescence microscopy. In contrast to the long
slender morphology of WT or DKO trypanosomes grown
in the presence of thymidine (Fig. 5A and B), most
thymidine-depleted DKO trypanosomes appeared shorter
and fatter with loss of their free ﬂagellum. In some
respects these are morphologically similar to the non-
dividing stumpy forms seen in relapsing infections which
are metabolically pre-adapted for growth in the tsetse ﬂy
vector midgut (Fairlamb and Opperdoes, 1986). However,
unlike stumpy forms, some had lost their ﬂagellum or
possessed two ﬂagella (Fig. 5C). A large vacuole at the
posterior end of the parasite was also evident, which,
by transmission electron microscopy, appeared to be a
grossly enlarged ﬂagellar pocket (Fig. 5F) compared with
Fig. 3. Growth characteristics of the T. brucei WT, SKO and DKO cells under various conditions.
A. Growth in HMI9 medium in the presence/absence of drug selection. WT, open circles; SKO plus puromycin, closed circles; DKO plus
puromycin and hygromycin, open squares; and DKO without drugs, closed squares. Open triangles show the growth of DKO without drugs in
HMI9 medium lacking the thymidine component.
B. Growth in folate-deﬁcient media (FDM) containing 160 mM thymidine. WT, open circles; SKO plus puromycin, closed circles; DKO plus
puromycin and hygromycin, open squares; and DKO without thymidine, closed squares.
Data are the means of triplicate cultures, where the standard deviations are 5% or less of the value. Symbols on the x-axis indicate that cell
densities are below the limits of detection (i.e. < 10
3 ml
-1). The lines represent the best ﬁts to the equation describing exponential growth as
described in Experimental procedures.
Fig. 4. Effect of pyrimidines on growth. Cells were grown in HMI9 medium supplemented with varying amounts of pyrimidines for 72 h and
cell density was determined using Alamar Blue as described in Experimental procedures.
A. WT plus thymidine, open circles; SKO plus thymidine, closed circles.
B. DKO plus thymidine, closed squares; DKO plus thymine, open squares (a complete lack of growth stimulation was also observed with uracil
or uridine).
The dashed line is the best ﬁt for growth stimulation and the dotted line is the best ﬁt for growth inhibition.
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respectively). The nucleus is also enlarged and is asso-
ciated with a noticeable increase in the number of glyco-
somes and lysosomes present throughout the sections
compared with normal WT and DKO cells. No evidence
for death by an apoptotic-like event was detected, either
by staining live cells with Annexin V-FITC (Wyllie and
Fairlamb, 2006) or by analysis of DNA for characteristic
fragmentation patterns (Ioannou and Chen, 1996) (data
not shown).
Effect of antifolate and PTR1 inhibitors
A range of DHFR–TS and PTR1 inhibitors were tested
against WT and DKO trypanosomes to assess speciﬁcity
against their predicted targets (see Fig. 1).As folate levels
in the culture medium can also modulate drug sensitivity,
EC50 values for growth inhibition were determined in
high- (HMI9; 8 mM) and low- (FDM; ~30 nM) folate media
(Table 1). In high-folate media, none of the nine inhibitors
tested were particularly effective against WT cells (EC50
values > 1 mM), whereas in low-folate media WT cells
became 68- to 310-fold more sensitive to the folate struc-
tural analogues, methotrexate, aminopterin and raltitr-
exed, with EC50 values ranging from 37 to 72 nM. The
toxicity of the other inhibitors against WT cells was similar
in both media. With DKO cells, none of the inhibitors
showed any increase in sensitivity when cultured in low-
folate media. Compared with WT, DKO cells are approxi-
mately ﬁvefold less sensitive in high-folate medium to the
DHFR inhibitors, aminopterin and methotrexate. Strik-
ingly, the DKO parasites were ~1000-fold less sensitive
Fig. 5. Phenotypic analysis WT and DKO cells grown in the presence or absence of thymidine. Cells were grown in either the absence or
presence of thymidine (dT) for 24 h and prepared for FACS, SEM, Giemsa, DAPI and TEM analysis. The histograms from the FACS analysis
are presented in (A) WT minus thymidine, (B) DKO plus thymidine, (C) DKO minus thymidine with SEM, Giemsa and DAPI images of the
respective cells in the right-hand panels. TEM showing the morphology of the WT (D), DKO plus thymidine (E) and DKO minus thymidine (F)
are depicted. Bars represent 1 mm. N, nucleus; NM, nuclear membrane; FR, ﬂagella rod; FP, ﬂagella pocket; Ax, axonemes; G, glycosome;
L, lysosome; PR, paraxial rod; MT, microtubules.
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Growth inhibition by the thymidylate synthase inhibitors,
raltitrexed and pemetrexed, was completely abolished in
DKO parasites, showing up to 11 000-fold resistance
compared with WT. There was no marked change in
sensitivity towards the lipophilic DHFR inhibitors
pyrimethamine, trimetrexate or to 5-ﬂuoro-oroate when
compared across media or cell type. Likewise, the known
PTR1 inhibitors belonging to the 2,4-diaminopteridine
class, O/129 and triamterene, were also unchanged.
Can endogenous PTR1 compensate for lack of DHFR?
PTR1 is known to reduce a broad spectrum of pterins and
folates (Dawson et al., 2006), raising the intriguing possi-
bility that it may compensate for changes in DHFR activity
in SKO and DKO lines. PTR1 levels in each cell line were
analysed for RNA and protein content by Northern and
Western blotting relative to suitable controls (Fig. 6). Den-
sitometry of RNA blots indicated that the absolute ratio of
DHFR–TS in WT, SKO and DKO is 1:0.5:0 (Fig. 6A).
Using INO1 [1-D-myo-inositol-3-phosphate synthase
(Martin and Smith, 2005)] as a loading control (Fig. 6C),
the corrected ratios are 1:0.6:0. PTR1 transcripts are only
marginally increased in SKO and DKO cell lines (1:1.1:1.1
respectively; Fig. 6B). After correction with INO1, the
corresponding values are 1:1.4:1.1. Protein blots were
probed with polyclonal antisera raised against T. brucei
PTR1 (Fig. 6D) and the endoplasmic reticulum chaperone
BiP (Fig. 6E). PTR1 levels are equal for all three cell lines,
with expression levels relative to BiP being 1:0.9:0.9 for
WT, SKO and DKO respectively.
Although PTR1 levels are unchanged in the knockout
lines, it is possible that endogenous activity is nonethe-
less sufficient to compensate for the loss of DHFR activity.
To determine whether the thymidylate cycle could be sus-
tained by endogenous PTR1, we constructed a recovery
plasmid containing the thymidylate synthase gene from
Escherichia coli. This plasmid (pLew82_EcTS) was able
to complement E. coli thyA - cells grown on thymidine-
deﬁcient medium indicating that TS was functional
(Fig. 7A). This expression construct was transfected into
DKO cells and lines selected for phleomycin resistance in
HMI9 medium. Integration of the EcTS in the conditional
DKO (cDKOTS) cells at the correct locus was conﬁrmed
by Southern blot analysis using the EcTS as a probe
(Fig. 7B). Growth was monitored in HMI9 (with and
without thymidine and/or tetracycline) to determine
whether the addition of TS alone could maintain the
Table 1. Sensitivity of WT and DKO to DHFR–TS and PTR1 inhibitors.
Inhibitor
WT DKO Ratio DKO/WT
EC50 HMI9
(mM)
EC50 FDM
(mM)
Ratio
EC50
EC50 HMI9
(mM)
EC50 FDM
(mM)
Ratio
EC50 HMI9 FDM
Methotrexate 2.5  0.2 (3)
a 0.037  0.007 (2) 68 17.9  6.5 (2) 22.2  5.2 (2) 0.8 7.2 484
Aminopterin 15.1  2.3 (2) 0.049  0.009 (3) 308 78.5  5.9 (2) 75.1  6.2 (2) 1.0 5.2 1 533
Raltitrexed 22.4  2.1 (3) 0.072  0.009 (3) 311 > 800 (2) > 800 (2) - > 36 > 11 111
Pemetrexed 1.8  0.1 (2) 1.9  0.3 (2) 0.9 > 800 (2) > 800 (2) - > 444 > 421
Pyrimethamine 17.2  2.7 (3) 9.6  1.3 (2) 1.8 35.6  4.5 (2) 27.6  2.6 (2) 1.3 2.1 2.9
Trimetrexate 1.2  0.1 (3) 3.2  0.3 (3) 0.4 4.1  0.6 (3) 5.6  0.8 (2) 0.7 1.9 1.8
5-Fluoro-orotic acid 2.8  0.3 (3) 1.4  0.3 (3) 1.6 4.2  0.7 (2) 2.5  0.5 (3) 1.7 1.9 1.7
O/129
b 16.5  1.7 (3) 7.4  1.2 (2) 2.2 17.9  2.1 (3) 9.7  1.1 (3) 1.8 0.9 1.3
Triamterene 48.3  5.1 (2) 45.2  3.6 (2) 1.1 15.9  1.1 (2) 58.9  7.8 (2) 0.3 0.3 1.3
a. n = number of independent experiments, where EC50 values are weighted means and standard errors of each independent determination.
b. 2,4-Diamino-6,7-diisopropylpteridine.
Fig. 6. Northern and Western blot analysis of WT, SKO and DKO
cells. Trypanosomes were grown for 24 h in HMI9 medium in the
absence (WT and SKO) or presence of thymidine (DKO).
A–C. RNA blots probed with TbDHFR–TS, TbPTR1 and TbINO1
respectively. RNA size markers are indicated to the left of the
panels.
D and E. Protein blots of parasite lysates probed with antiserum to
PTR1 and BiP respectively. Approximately 20 mg of protein was
loaded per lane. Standard size markers are indicated to the right of
the panels.
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TS add-back grew normally in HMI9 containing thymidine
(generation times 13 and 13.4 h, respectively, with or
without tetracycline), but, in its absence, no viable trypa-
nosomes were visible beyond day 4. Nonetheless, when
compared with the DKO grown in the absence of thymi-
dine, survival was prolonged by 2 and 3 days, respec-
tively, in the absence and presence of tetracycline.
To demonstrate that the E. coli TS was also functional
in T. brucei, extracts were prepared from cell lines cul-
tured in the presence of thymidine and assayed radio-
metrically for enzyme activity (Fig. 8). Irrespective of
tetracycline induction, cDKOTS cells showed ~10-fold
greater enzymatic activity than WT cells (2838  1438
cpm) conﬁrming that functional TS is present in this trans-
genic line. The DKO line showed activity that was not
signiﬁcantly different from zero (862  1283 cpm), con-
ﬁrming the absence of TS activity as demonstrated by
thymidine auxotrophy (Figs 3 and 4).
To demonstrate that deletion of DHFR–TS had not
resulted in other genomic mutations, a copy of
TbDHFR–TS (with two internal HindIII restriction sites
ablated) was cloned into pLew100 (Wirtz et al., 1999).
The resulting construct was able to rescue thyA - E. coli
(Fig. 7D) indicating that the modiﬁed TbDHFR–TS was
functional. pLew100_TbDHFR–TS was then transfected
Fig. 7. Complementation studies with EcTS and TbDHFR–TS. (A)–(C) Complementation with E. coli TS and (D)–(F) complementation with
T. brucei DHFR–TS.
A. Growth of E. coli thyA
- transformed with pLew82_EcTS or empty vector on thymidine-free medium.
B. Southern analysis of T. brucei DKO transfected with pLew82_EcTS (cDKOTS). DNA was digested with SacI and SphI and probed with EcTS
ORF. The size of the expected fragment is indicated on the right with standard markers on the left.
C. Growth of cDKOTS in HMI9 medium with or without thymidine. Circles, plus thymidine; squares, no thymidine present. Open symbols depict
growth without tetracycline induction and closed symbols with tetracycline. Triangles, growth of DKO in the absence of thymidine. The lines
represent the best ﬁts to the equation describing exponential growth as described in Experimental procedures.
D. Growth of E. coli thyA
- transformed with pLew100_TbDHFR–TS or empty vector on thymidine-free medium.
E. Southern analysis of T. brucei DKO transfected with pLew100_TbDHFR–TS (cDKODHFR–TS). DNA was digested with HindIII and StuI and
probed with TbDHFR–TS. The size of the expected fragment is indicated on the right with standard markers on the left.
F. Growth of cDKODHFR–TS in HMI9 medium with and without thymidine (open and closed circles respectively). Open squares, growth of DKO in
the absence of thymidine. The lines represent the best ﬁts to the equation describing exponential growth as described in Experimental
procedures.
Symbols on the x-axis indicate that cell densities are below the limits of detection (i.e. < 10
3 ml
-1).
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the ribosomal DNA locus resulting in cDKODHFR–TS cells
(Fig. 7E). cDKODHFR–TS cells were able to grow in the
absence of thymidine, with or without induction by tetra-
cycline (generation times for both are 12 h; Fig. 7F).
Enzymatic activity approaching WT levels was found in
this cell line (Fig. 8), conﬁrming that TS was functional.
Loss of tetracycline control is a frequently observed phe-
nomenon with the pLew family of vectors (Krieger et al.,
2000; Milne et al., 2001; Chang et al., 2002; Martin and
Smith, 2006a). Loss of expression of the TETR protein or
mutation or ablation of the tet operator site has been
proposed as possible mechanisms of escape from tetra-
cycline repression. However, only one study has demon-
strated that this results from deletion of the TETR gene
(Roper et al., 2002). This is not the case here, as PCR
conﬁrmed the presence of TETR (not shown). Thus, loss
of tetracycline control in our experiments must be due to
another mechanism.
Virulence in mice
The nutritional environment in vivo is considerably differ-
ent from in vitro culture conditions underlining the need
for target validation studies to be carried out in animal
models, where possible (Frearson et al., 2007). To
conﬁrm the essentiality of DHFR–TS, mice were inocu-
lated with WT or genetically modiﬁed parasites and the
course of the infection monitored over a 30-day period. A
survival curve for the various infections is shown in Fig. 9.
Mice infected with WT cells were unable to survive
beyond 3–4 days, whereas DKO-infected mice remained
completely free of parasites and survived beyond
30 days. This indicates that the thymidine level in mouse
plasma (1 mM; Clarke et al., 2000) is not sufficient to
sustain DKO cell viability in vivo, consistent with the in
vitro data presented in Fig. 4. Virulence was restored in
cDKODHFR–TS cells indicating that the selectable markers
PAC and HYG had not suppressed the virulence
phenotype. SKO infections were also lethal. In one experi-
ment with SKO (PAC), survival times were extended to up
to 16 days, but this was not reproduced in a second
experiment. Virulence of a second single-knockout line
(SKO HYG) was also similar to WT, except for one mouse
that remained aparasitaemic throughout the 30-day
experiment. These results demonstrate deﬁnitively that
DHFR–TS is absolutely essential for parasite survival in
the host. They also suggest that sustained inhibition of
DHFR–TS by >50% would be required for a chemothera-
peutic effect.
Discussion
The genetic studies presented here clearly indicate that
DHFR–TS is essential for growth and survival of the
African trypanosome in vitro and in vivo. Nutritional
rescue of the DHFR–TS null is speciﬁc for thymidine and
cannot be replaced by other pyrimidines, consistent with a
speciﬁc requirement of both enzymes in the thymidylate
cycle (Fig. 1). The ﬁnding that PTR1 levels are unchanged
4 × 104
3 × 104
2 × 104
104
0
WT
cDKO EcTS –
cDKO EcTS +
cDKO DHFR-TS +
DKO
[
3
H
]
-
w
a
t
e
r
 
r
e
l
e
a
s
e
d
,
 
c
p
m
Cell line
Fig. 8. TS activity in WT and transgenic T. brucei. TS activity was
determined by release of [
3H]-water from [
3H]-dUMP as described
in Experimental procedures. Error bars represent the standard error
of triplicate assays. The minus and plus signs refer to growth in
HMI9 medium in the absence or presence of tetracycline
respectively.
Fig. 9. Virulence of WT, SKO and DKO
T. brucei infections in mice. Each data set
represents the combined results of two
independent experiments presented as a
Kaplan–Meier survival plot. The ﬁgures in the
legend are the numbers of survivors per
infected group. As the cDKODHFR–TS was not
responsive to tetracycline induction these data
sets have been combined. Symbols: WT, dark
blue; SKO (PAC), green; SKO (HYG), light
blue; DKO, black; cDKO, red.
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achieved by ectopic expression of TbDHFR–TS, but not
with functionally active EcTS, suggests that PTR1 is
unable to compensate for complete loss of DHFR activity.
PTR1 from T. brucei is fourfold less efficient in reducing
dihydrofolate than the L. major enzyme and is less sensi-
tive to inhibition by methotrexate (Dawson et al., 2006).
However, it is pertinent to note that DHFR mutants in
E. coli are always associated with compensatory muta-
tions in ThyA to maintain the delicate balance between
formation and removal of dihydrofolate by TS and DHFR
respectively (Ahrweiler and Frieden, 1988; Howell et al.,
1988). Thus, the failure to restore viability with EcTS could
be due to an imbalance between PTR1 and TS activity,
which is 10-fold higher than in WT cells. Moreover,
although DHFR in T. brucei may be a drug target per se
without recourse to inhibiting PTR1, ampliﬁcation of PTR1
could represent a potential resistance mechanism to
DHFR inhibitors, as observed in Leishmania spp. (Bello
et al., 1994; Nare et al., 1997b; Ouellette et al., 2002).
However, unlike Leishmania spp., gene ampliﬁcation in
African trypanosomes is extremely rare. To our knowl-
edge, ampliﬁcation of the inosine monophosphate dehy-
drogenase gene in Trypanosoma gambiense in response
to selection by mycophenolic acid is the only example
reported in the literature (Wilson et al., 1994).
The fact that T. brucei DHFR–TS null mutants are non-
viable in vivo is in contrast to L. major DHFR–TS null
mutants, which cause persistent avirulent infections in
mice. Presumably, this is due to sufficient amounts of
thymidine being available in the parasitophorous vacuole
of the host macrophage (Titus et al., 1995). This interest-
ing phenomenon of persistence has been exploited as a
potential live vaccination strategy in leishmaniasis (Veras
et al., 1999). In complete contrast, T. brucei DKO lines are
totally incapable of establishing or maintaining an infec-
tion in mice. Given the narrow window of thymidine con-
centrations that can support growth of T. brucei in vitro,
this is likely to be a consequence of the extremely low
concentrations of thymidine in plasma: ~1 mM in mice or
~0.1 mM in humans (Clarke et al., 2000).
The underlying mechanisms involved in ‘thymine-less
death’ in prokaryotes and eukaryotes are not fully under-
stood (Ahmad et al., 1998). The primary event following
inhibition of TS activity is extreme depletion of the dTTP
pool with a concomitant increase in dUMP and its subse-
quent phosphorylation to form dUTP (Van Triest et al.,
2000; Ackland et al., 2003; Gmeiner, 2005). If the capacity
of dUTPase to hydrolyse dUTP is exceeded, then a futile
cycle of misincorporation of uracil into DNA, followed by
base excision by uracil-DNA glycosylase, takes place,
ultimately causing irreparable chromosome damage and
cell death (Ahmad et al., 1998; Van Triest et al., 2000;
Tinkelenberg et al., 2002). However, we found no
evidence for death by an apoptotic-like mechanism as
frequently observed in higher eukaryotes (Van Triest
et al., 2000). Rather, the morphological phenotype of an
enlarged ﬂagellar pocket observed here resembles the
‘big-eye’ phenotype reported for clathrin knock-down by
RNAi in T. brucei (Allen et al., 2003). It is not immediately
apparent what the common mechanism might be, if any.
Further studies on the biochemical processes leading to
cell death due to thymidine depletion are required.
The inhibitors used in this study have uncovered some
interesting features of folate metabolism in T. brucei with
potential implications for target validation and drug
discovery. Phenotypic drug screening against these para-
sites using standard HMI9 medium is not ideal for inhibi-
tors targeting folate and thymidylate metabolism. For
example, high folate levels markedly attenuate the cyto-
toxic effect of antifolate inhibitors such as methotrexate
and aminopterin (both DHFR inhibitors) and raltitrexed (a
TS inhibitor) that are structurally similar to physiological
folates. The precise mechanism of attenuation remains to
be determined, but the high folate in HMI9 medium could
competitively inhibit drug uptake into cells, interfere with
cellular retention by competition for polyglutamylation by
folylpolyglutamyl synthetase or compete for the active
sites of target enzymes as reported for mammalian
systems (Kane et al., 1986; Jansen et al., 1989; 1998;
Barnes et al., 1999; Backus et al., 2000; van der Wilt
et al., 2001). Interestingly, the trypanocidal potency of
the TS inhibitor, pemetrexed (Wang et al., 2003), is not
affected by high folate levels in the medium, despite a
pronounced (440-fold) decrease in potency against the
DKO cell line. This may be due to a different mode of
uptake or reduced polyglutamylation compared with the
other folate analogues. Further transport and metabolism
studies are required to test these possibilities.
Deletion of DHFR–TS causes a huge loss in inhibitor
potency (>500-fold) in cells cultured in low-folate medium,
indicating that these enzyme activities are the primary
targets for methotrexate, aminopterin, raltitrexed and
pemetrexed. However, this effect is not observed with
lipophilic inhibitors such as pyrimethamine, a potent
inhibitor of TbDHFR (Gamarro et al., 1995), or trime-
trexate, a potent inhibitor of Trypanosoma cruzi DHFR
(Ki
app6.6 nM) which has an EC50 of 26 nM against T. cruzi
amastigotes (Senkovich et al., 2005). Neither is it
observed for 5-ﬂuoro-orotate, a prodrug of 5-FdUMP. The
reason for this is not known. However, the high concen-
trations (>1 mM) required to inhibit growth point to factors
such as poor cellular pharmacokinetics (absorption, dis-
tribution, metabolism and excretion) or poor potency
against the target with other ‘off-target effects’ predomi-
nating in cell killing. The latter explanation is likely in the
case of 5-ﬂuo-orotate, as ﬂuorinated pyrimidine ana-
logues are known to have pleiotropic effects such as
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Triest et al., 2000). Interestingly, the sensitivity of T. brucei
to raltitrexed and 5-ﬂuoro-orotate is the inverse of what is
observed for malaria parasites, where raltitrexed (ICI
D1694) is virtually inactive (EC50 >20 mM) (Rathod and
Reshmi, 1994), yet 5-ﬂuoro-orotate is highly active (EC50
6 nM) (Rathod et al., 1989).
In conclusion, we have evaluated DHFR–TS as a drug
target in African trypanosomes and obtained deﬁnitive
genetic evidence and compelling chemical evidence sug-
gesting that these enzymes are sufficiently validated to
warrant entry into a drug discovery pipeline. Enzymatic
and structural studies of this enzyme are underway to
facilitate this process.
Experimental procedures
Trypanosome culture
Trypanosoma brucei bloodstream-form ‘single marker’ S427
(T7RPOL TETR NEO) and knockouts were cultured in HMI9
medium (Hirumi and Hirumi, 1989) supplemented with
2.5 mgm l
-1 G418 to maintain expression of T7 RNA poly-
merase and the tetracycline repressor protein (Wirtz et al.,
1999). HMI9 medium contains high concentrations of folate
principally from the Iscove’s modiﬁed Dulbecco’s medium
(IMDM) and the 10% (v/v) Serum Plus components (SAFC
Biosciences). Serum Plus is a proprietary medium supple-
ment containing 20% fetal bovine serum (FBS), growth-
promoting factors, hormones, lipids and 2.72 mg l
-1 folic acid
(6.2 mM folate, excluding FBS; personal communication from
SAFC Biosciences). HMI9 therefore contains 7.9 mM folate,
not including folate from FBS (12% v/v, ﬁnal). Folate free
IMDM is not commercially available, so a FDM equivalent to
HMI9 was prepared using folate-free RPMI 1640 supple-
mented with 50¥ MEM amino acid solution (Invitrogen) to
provide amino acid and other nutrient concentrations equiva-
lent to those found in HMI9 (see Table S1). Other compo-
nents were the same as HMI9 (14 mM glucose, 25 mM
HEPES, 2 mM pyruvate, 0.5 mM bathocuproine disulphonic
acid, 1.5 mM cysteine, 0.2 mM 2-mercaptoethanol, 1 mM
hypoxanthine, 0.16 mM thymidine and 10% FBS) except
Serum Plus was reduced to 0.5% so that the total FBS was
10.1% (see Table S1). Excluding the contribution from the
serum components, FDM contains 31 nM folate.
Cultures were initiated with 1 ¥ 10
5 cells ml
-1 and subcul-
tured when cell densities approached 1–2 (¥ 10
6)m l
-1. The
single marker WT, SKO and DKO cell lines were also grown
continuously in the presence of the appropriate drug selec-
tion (see below for further details). Once established, DKO
cell lines were also grown in the absence of additional drug
selection. Generation times (g) were determined by non-
linear regression using GraFit with proportional weighting
ﬁtted to the following equation:
NN
tg = 02
where N0 is the starting cell density at zero time and N is cell
density at time, t.
Generation of knockout and recovery constructs
Primers used in this study (Table S2) are based on the
T. brucei DHFR–TS GeneDB sequence (Tb927.7.5480, 927
strain) and E. coli ThyA (Accession No. J01710, K-12,
MG1655 strain). All constructs were sequenced to conﬁrm
correct assembly. To generate the T. brucei gene replace-
ment cassettes, the region containing the 303 bp of the
5′-UTR to the 286 bp 3′-UTR ﬂanking the open reading frame
(ORF) of T. brucei DHFR–TS was ampliﬁed from genomic
DNA, using Pfu polymerase. This was used as a template for
the ampliﬁcation of the individual regions for the assembly of
the replacement cassettes containing the selectable drug
resistance genes puromycin N-acetyl transferase (PAC)
and hygromycin phosphotransferase (HYG), as previously
described (Martin and Smith, 2006b). To generate a recovery
construct pLew100_TbDHFR–TS, the DHFR–TS ORF was
ampliﬁed using TbDHFR–TS-XhoI fwd and TbDHFR–TS-
BamHI rev primers, and cloned into pCR-Blunt II TOPO
(Invitrogen). This was used to introduce silent mutations to
remove two HindIII sites within the gene at Leucine 236
(L236) andAlanine 452 (A452) sequentially with the following
sets of primers HindIII-L236 fwd, HindIII-L236 rev and HindIII-
A452 fwd HindIII-A452 rev respectively (Table S2). This
TOPO clone was used as a template to generate a PCR
product containing 5′-HindIII and 3′-PacI restriction sites
which was subcloned into a modiﬁed pLew100 vector con-
taining blasticidin S transferase (BSD) replacing NEO as
the selectable gene marker (kindly supplied by Dr Kirstee
Martin).
The recovery construct, pLew82_EcTS containing the
E. coli gene for thymidylate synthase (ThyA), was engineered
as follows. ThyA (Accession No. J01710) was ampliﬁed from
E. coli (K-12, MG1655 strain) gDNA using EcThyA-HindIII
fwd and EcThyA-BamHI rev primers (Table S2) and the
product cloned into pCR-Blunt II TOPO (TOPO_EcTS). The
ORF was subcloned into pLew82 containing the resistance
marker gene bleomycin.
Generation of an E. coli thyA - cell line and functional
complementation of TS recovery constructs
An E. coli thymidylate synthase deﬁcient (thyA
-) cell line
derived from E. coli BL21 (DE3) Star cells (Invitrogen) was
engineered using the TargeTron™ Gene Knockout System
(Sigma-Aldrich) as described in the manufacturer’s
instructions. Brieﬂy, the TOPO_EcTS clone was used as the
template for the intron retargeting PCR using primers IBS-
EcThyA and EBS2-EcThyA (Table S2) that were chosen at
Sigma’s TargeTron Design Site (http://www.sigma-genosys.
com/targetron/). The disrupted thyA
- cells were selected
using kanamycin and ThyA-speciﬁc disruption was veriﬁed by
colony-PCR screening using EcThyA-HindIII fwd and EBS2-
EcThyA primers. The resulting thyA
- E. coli was transformed
with the pLew82_EcTS or pLew100_TbDHFR–TS recovery
constructs and plated out onto LB containing 50 mgm l
-1 car-
benicillin and 1 mgm l
-1 tetracycline to conﬁrm that these plas-
mids contained a functional thymidylate synthase gene.
Negative controls of the empty vector and cells alone were
included.
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Knockout and recovery constructs were prepared using
QIAprep Miniprep Plasmid Kit (Qiagen). DNA was digested
with NotI, ethanol precipitated and redissolved in sterile water
at a ﬁnal concentration of 1 mg ml
-1. Trypanosomes were
electroporated as described previously (Wirtz et al., 1999;
Chang et al., 2002; Roper et al., 2002; Martin and Smith,
2006b). Transformed SKO cells containing the PAC or HYG
genes were cultured in the presence of 0.1 mgm l
-1 puromycin
or 4.0 mgm l
-1 hygromycin respectively. The SKO PAC line
was used to produce a DKO line using the HYG knockout
construct to replace the second endogenous copy of
DHFR–TS by selection with hygromycin and puromycin.
Transfection of the pLew82_EcTS and pLew100_
TbDHFR–TS recovery constructs into the DKO cells resulted
in the selection of conditional DKO (cDKO) cells with
2.5 mgm l
-1 phleomycin and blasticidin respectively.
DNA and RNA analysis of KO cells
Conﬁrmation of the correct integration of the knockout and
recovery constructs was undertaken with restriction digests
of 5 mg of gDNA with subsequent Southern blot analysis as
described previously (Martin and Smith, 2006b) using DNA
probes speciﬁc for DHFR–TS, PAC, HYG and ThyA. RNA
was prepared from approximately 2 ¥ 10
8 cells (WT and SKO
cells grown in HMI9 lacking thymidine and DKO cells in
HMI9) using Qiagen RNeasy Mini Kit. The RNA samples
(5 mg) were denatured in formaldehyde/formamide premix
at 65°C for 15 min and run on a 1.2% agarose/2%
formaldehyde/1¥ MOPS gel and transferred to Hybond-N
nylon membrane (Amersham Biosciences). Blots were
hybridized sequentially with [a-
32P]-dCTP-labelled probes for
TbPTR1, TbDHFR–TS and TbINO1 prepared with Rediprime
(Amersham Biosciences).
Western blot analysis of cell lysates
Polyclonal antisera against T. brucei PTR1 were raised in
adult male Wistar rats. An initial injection of 100 mg of puriﬁed
antigen (Dawson et al., 2006), emulsiﬁed in complete
Freund’s adjuvant, was followed by two identical booster
injections of antigen emulsiﬁed in Freund’s incomplete
adjuvant at 2-week intervals.
Wild-type and SKO trypanosomes were grown in
thymidine-deﬁcient HMI9 media while DKO cells were grown
in HMI9 supplemented with thymidine. Mid-log cells (~1 ¥ 10
9
cells) were harvested by centrifugation (800 g, 10 min, 25°C),
aspirated and pellets re-suspended in 1 ml of ice-cold PBS
(137 mM NaCl, 8 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4,
pH 7.4) containing a cocktail of protease inhibitors (Calbio-
chem, Protease Inhibitor Cocktail Set III). Following centrifu-
gation (5000 g, 2 min, 25°C), cell pellets were further
re-suspended in 500 ml of ice-cold PBS containing protease
inhibitors, 1 mM EDTA and 1 mgm l
-1 of both DNase and
RNase. For biological safety, samples were freeze-thawed
ﬁve times prior to mechanical disruption with sterile glass
beads (Sigma, bore size 425–600 mm) in a micro pestle.
Lysates were centrifuged (13 000 g, 20 min, 4°C), the result-
ing supernatants were collected and protein concentration
was determined.
Cell extracts (20 mg) were then separated on SDS-PAGE
and subsequently transferred onto nitrocellulose. After block-
ing with 5% skimmed milk in PBS at room temperature for
1 h, the blot was incubated with T. brucei PTR1 polyclonal
antiserum (1/1000 dilution) or T. brucei BiP (kindly supplied
by Dr M.L. Güther, originally from Dr J. Bangs) at room
temperature for 1 h, washed in PBS containing 0.1% (v/v)
Tween 20 and then incubated with a secondary rabbit anti-rat
(IgG) antibody (Dako; 1/10 000 dilution). The immunoblots
were subsequently developed using the ECL
® plus
(enhanced chemiluminescence) system from Amersham
Biosciences.
Thymidylate synthase assays
Thymidylate synthase activity in cell lysates was carried out
as described (Nirmalan et al., 2004) with minor modiﬁcations.
Approximately 2 ¥ 10
8 cells were prepared from WT, DKO,
cDKODHFR–TS (with tetracycline induction), cDKOTS (with and
without tetracycline induction), osmotically lysed with ice-cold
distilled water, frozen and thawed three times in liquid nitro-
gen and ﬁnally re-suspended in an equal volume of 2¥ TS
assay buffer (0.4 M Tris-HCl pH 7.4 containing 2 mM EDTA,
40 mM 2-mercaptoethanol, 200 mM NaF and 30 mM CMP).
The suspension was centrifuged for 10 min, at 12 000 g at
4°C and the resulting supernatant was used to determine the
TS activity. This involves a tritium release assay using [5-
3H]-
dUMP (Moravek Biochemicals) and (6R,S)-5,10-methylene-
5,6,7,8-tetrahydrofolic acid (Schircks Laboratories). In brief
the standard assay consisted of 200 ml of cell lysate prepared
in TS assay buffer with the addition of 5 ml of 6.5 mM
methylene tetrahydrofolate and 5 ml of [5-
3H]-dUMP
(19 Ci mmol
-1). Assay mixtures were incubated at 37°C for
1 h and reactions stopped with the addition of 50 ml of ice-
cold 100% (w/v) TCA. After incubation for 10 min on ice,
residual [5-
3H]-dUMP was removed by ﬁve extractions with
activated charcoal suspension. After the ﬁnal extraction step,
200 ml of aqueous supernatant was counted in 3 ml of scin-
tillation ﬂuid. Samples were analysed in triplicate and back-
ground counts subtracted from negative control reaction
mixtures containing heat-inactivated lysate.
EC50 determination of inhibitors against WT and
DKO cells
Antifolates were tested against WT and DKO cells in HMI9
and FDM (both containing 160 mM thymidine). Serial doubling
dilutions of drugs (10–20 dilutions from 10 mM stocks pre-
pared in 10% DMSO) were added to ﬂat-bottomed 96-well
plates containing 1 ¥ 10
4 cells ml
-1 in a ﬁnal volume of 0.2 ml
in either HMI9 or FDM. Plates were incubated for 72 h at
37°C/5% CO2 and cell densities were determined using
Alamar Blue (Raz et al., 1997). EC50 values were calculated
using GraFit software (Erithacus Software) with a non-linear
4-parameter robust curve ﬁt in triplicate. All inhibitors were
from Sigma Chemical, except pemetrexed (International
Laboratory USA), trimetrexate (Tocris) and raltitrexed
(Tomudex, ZD1694, from Astra Zeneca).
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Wild-type and DKO cells were grown to 1 ¥ 10
6 cells ml
-1 in
HMI9 medium, centrifuged (2500 g, 10 min, 25°C) and
washed twice in HMI9 medium lacking thymidine. The cell
pellets were re-suspended in thymidine-deﬁcient medium
and incubated for a further 24 h. Cells were collected by
centrifugation and washed twice in PBS before preparation
for FACS analysis (Tu and Wang, 2005). Cells were ﬁnally
adjusted to 5 ¥ 10
5 cells ml
-1, re-suspended in 500 mlo fP B S
containing 50 mgm l
-1 propidium iodide, 50 mgm l
-1 RNase
and 0.1% Triton X-100, incubated at room temperature for
20 min in the dark and analysed using FACSort analytical
ﬂow cytometer using Cellquest software (BD Biosciences).
Morphological analysis
Cells were examined following ﬁxation with methanol or 4%
(v/v) paraformaldehyde and stained with Giemsa or 4′,6-
diamidino-2-phenylindole (DAPI), respectively, using a Carl
Zeiss light and ﬂuorescent microscope. For electron micros-
copy, WT and DKO cells (grown in the presence and absence
of thymidine) were ﬁxed for 24 h in 2% (v/v) glutaraldehyde
and 4% (v/v) paraformaldehyde in 0.2 M PIPES, pH 7.2. For
transmission electron microscopy cells were prepared as
described previously (Broadhead et al., 2006), post-ﬁxed for
1 h at 4°C with 1% (v/v) osmium tetroxide in 100 mM phos-
phate buffer (pH 6.5) and rinsed brieﬂy in water prior to ﬁxing
or staining en bloc with 3% (v/v) aqueous uranyl acetate.
Cells were rinsed further in distilled water and subsequently
dehydrated through a graded ethanol series with a ﬁnal wash
in propylene oxide, prior to embedding in Durcupan resin.
Sections were stained with 3% (v/v) aqueous uranyl acetate
and Reynold’s lead citrate prior to examination using a JEOL-
1200 EX TEM. For scanning electron microscopy, the same
ﬁxation and en block staining protocol was applied. After
ethanol dehydration series the samples were critical-point
dried and the membranes coated with gold-palladium by
sputter staining and examined using a Philips XL 30 SEM.
In vivo studies
All cell lines were cultured for 24 h in the absence of select-
able drugs before mice (ﬁve per group) were infected with a
single intraperitoneal injection of 10
5 parasites in 0.2 ml of
glucose saline. One set of animals were administered with
2.5 mgm l
-1 doxycycline in their drinking water 3 days prior to
infection with the cDKODHFR–TS and freshly prepared every
second day for the duration of the experiment. Animals were
inspected daily for clinical signs of infection (reduced activity,
ruffled fur, increased respiration and prostration or collapse)
and wet smears of tail blood were examined microscopically
(¥40 lens and ¥10 objective) in 20 high-power ﬁelds for
parasites. When more than ﬁve parasites were visible per
high-power ﬁeld 1 ml of tail blood was drawn by capillary
action into a Microcap glass capillary (Sigma), diluted 200-
fold with glucose saline and parasite density was determined
microscopically using a Neubauer haemocytometer. Any
animal with a parasitaemia exceeding 1 ¥ 10
8 ml
-1 was
humanely killed as pilot experiments had established that
animals were unable to survive a further 24 h with WT (SM)
strain.
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